Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
jRCTs041260166
Key facts
Open-label, single-arm trial of bimekizumab in plaque psoriasis, sponsored by UCB. Primary endpoint: PASI 100 achievement rate at week 16. Started Nov 2026; status: recruiting.
Single treatment cohort
All participants receive bimekizumab initially, with post-week-16 branching based on PASI 100 achievement.
Adults with plaque psoriasis requiring biologic-level treatment are eligible if disease duration is either less than 2 years or more than 10 years and they have inadequate response to existing systemic therapy/phototherapy with body surface area involvement of at least 10%, or DLQI greater than 10, or refractory lesions in difficult areas with PASI of at least 5. Patients with clinically significant active psoriatic arthritis needing treatment escalation, severe infection, active tuberculosis, pregnancy, recent interventional trial participation, or extensive prior biologic exposure are…
PASI 100 achievement rate at week 16
Remission maintenance period and maintenance rate after discontinuation
Change over time in psoriasis severity and quality-of-life indices
Changes in concomitant medication use
Serum chemokine and cytokine exploratory analyses
Skin biopsy exploratory analyses
Beyond the preview
Full results, competitive context and analysis are in the Gosset platform.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on jRCTs041260166.